Skip to main content

Published locations for FDA approves acalabrutinib for second-line treatment of MCL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA approves acalabrutinib for second-line treatment of MCL

User login

  • Reset your password
  • /content/fda-approves-acalabrutinib-second-line-treatment-mcl
  • /hematologynews/article/150776/mantle-cell-lymphoma/fda-approves-acalabrutinib-second-line-treatment
  • /oncologypractice/article/150776/mantle-cell-lymphoma/fda-approves-acalabrutinib-second-line
  • /hematology-oncology/article/150776/mantle-cell-lymphoma/fda-approves-acalabrutinib-second-line
  • /b-cell-lymphoma-icymi/article/150776/mantle-cell-lymphoma/fda-approves-acalabrutinib-second-line